Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Core Insights - Myriad Genetics has announced a research collaboration with the National Cancer Center Hospital East in Japan to study the prognostic and predictive value of molecular residual disease (MRD) testing [1][2] - The SCRUM-MONSTAR-SCREEN-3 study will utilize Myriad's Precise MRD test to monitor circulating tumor DNA (ctDNA) in patients with various solid tumor and hematological cancers [1][2] Company Overview - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health and well-being through genetic insights that improve patient care and reduce healthcare costs [5] - The company develops genetic tests that assess disease risk and guide treatment decisions across multiple medical specialties [5] Study Details - The SCRUM-MONSTAR-SCREEN-3 study will involve approximately 1,200 patients across more than 20 cancer types, with two of the three cohorts undergoing MRD monitoring using the Precise MRD test [2] - The study aims to generate high-quality clinical evidence supporting the broad application of MRD testing across different cancer types and disease severities [2] Technology and Innovation - Myriad's Precise MRD is a tumor-informed, whole genome sequencing-based test that monitors hundreds to thousands of tumor-specific variants, providing exceptional sensitivity in detecting ctDNA [4] - The test can be utilized throughout a cancer patient's clinical journey, from diagnosis to treatment and surveillance [4] Expert Commentary - Dr. Takayuki Yoshino emphasized the need for a highly sensitive MRD test for cancers with low tumor shedding, highlighting the unique capabilities of Myriad's assay [3] - Dale Muzzey, Chief Scientific Officer at Myriad, expressed enthusiasm for collaborating with NCCHE, noting their leadership in MRD research and the potential impact of the study on cancer care [3]